People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Other Technology, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Valeritas Inc | — | Other Technology | Series C | $106.5M | $689.9M | 2011 |
| Vascular Pharmaceuticals, Inc. | — | Biotechnology | Series B | $47.3M | $119.1M | 2012 |
| Cerimon Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.7M | $8.9M | 2009 |
Vaughn Kailian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vaughn Kailian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Ryan | 1 | 17 |
| Todd Foley | 1 | 12 |
| Ansbert Gadicke | 1 | 7 |
| Ittai Harel | 1 | 6 |
| Richard Kent | 1 | 5 |
| Daniel Pelak | 1 | 5 |
| Robert Adelman | 1 | 5 |
| Richard Shea | 1 | 5 |
| Michael Bigham | 1 | 3 |
| Sean Traynor | 1 | 3 |
| Kristine Peterson | 1 | 3 |
| James H. Welch | 1 | 3 |
| John Barr | 1 | 3 |
| Ken Williams | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| William Duke | 1 | 2 |
| James Dentzer | 1 | 2 |
| Gary Patou | 1 | 2 |
| Elizabeth Stoner | 1 | 2 |
| Paul Hastings | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.